Severe Asthma Research Program

Status: Active_not_recruiting
Location: See all (8) locations...
Study Type: Observational
SUMMARY

The mission of the SARP is to improve the understanding of severe asthma through integrated study of its clinical and biological features and to evaluate their changes over time. The ultimate goal of these efforts is to promote better treatments for severe asthma.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 6
Healthy Volunteers: t
View:

• Physician diagnosis of asthma,

• Age 6 years and older

• Evidence of historical reversibility, including either:

‣ FEV1 bronchodilator reversibility ≥ 12%, or

⁃ Airway hyperresponsiveness reflected by a methacholine PC20 ≤16 mg/mL.

• History of chronic diseases that affect the lungs,

• A history suggestive of allergic rhinitis, eczema or chronic sinusitis,

• An improvement in FEV1 of more than 12% following 4 puffs of albuterol,

• Smoking history \> 10 pack years if ≥30 years of age, or smoking history \> 5 pack years if \<30 years of age, or any smoking within the past year,

• Respiratory tract infection within the past 4 weeks,

• Pregnancy,

• History of premature birth (\<35 weeks).

Locations
United States
California
University of California, San Francisco
San Francisco
Massachusetts
Brigham & Women's Hospital
Boston
Children's Hospital, Boston
Boston
Missouri
Washington University
Saint Louis
North Carolina
Wake Forest University Health Sciences
Winston-salem
Ohio
Cleveland Clinic
Cleveland
Pennsylvania
University of Pittsburgh
Pittsburgh
Wisconsin
University of Wisconsin-Madison
Madison
Time Frame
Start Date: 2012-10
Completion Date: 2026-12-31
Participants
Target number of participants: 1100
Treatments
Asthmatics
Subjects with active asthma.
Healthy Controls
Subjects without any known pulmonary disease.
Related Therapeutic Areas
Sponsors
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Leads: Milton S. Hershey Medical Center

This content was sourced from clinicaltrials.gov

Similar Clinical Trials